A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy and Hospitalization

Disease Activity, ANCA and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis

(2010) Matthias Jürgens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy of TNF Antagonists Beyond One Year in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Review

(2010) Abderrahim Oussalah et al.   CURRENT DRUG TARGETS

W1121 Clinical Efficacy and Mucosal Healing Rate of Infliximab in Steroid-Dependent Ulcerative Colitis: A Prospective Long-Term Follow-Up Study

(2009) Manuel Barreiro et al.   GASTROENTEROLOGY

W1143 Long-Term Scheduled Therapy with Infliximab in Inflammatory Bowel Disease

(2009) Alessandro Armuzzi et al.   GASTROENTEROLOGY

Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab

(2009) William J. Sandborn et al.   GASTROENTEROLOGY

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

(2009) C H Seow et al.   GUT

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis

(2009) I. Arijs et al.   GUT

W1262 Prospective, Open Pilot Study for Evaluating the Clinical Efficacy and Mucosal Healing Rate of Infliximab in Steroid-Dependent Ulcerative Colitis

(2008) Manuel Barreiro et al.   GASTROENTEROLOGY

European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis

(2008) E.F. Stange et al.   Journal of Crohns & Colitis

Long-term outcome after infliximab for refractory ulcerative colitis

(2008) Marc Ferrante et al.   Journal of Crohns & Colitis